FDA peptide compounding list 2026: six peptides the committee backed

The Pharmacy Compounding Advisory Committee is the outside expert panel the FDA consults on which bulk drug substances should be allowed in 503A compounding, meaning patient specific preparations made by a pharmacy on a prescription. Substances get nominated, FDA staff review the evidence and make a recommendation, and the committee votes. On July 23 and 24, 2026 the committee took up seven peptides in one sitting.

FDA's reviewing scientists recommended against adding any of the seven, citing the gaps that run through this site's compound pages: no completed human trials for most of them, no established safety profile, unknown immunogenicity and, for several, theoretical concerns about mechanism. The committee then voted the other way on six, with narrow margins and several abstentions. For Semax the recommendation was tied to specific uses, cerebral ischemia, migraine and trigeminal neuralgia, and for Epitalon to insomnia, which would limit what a pharmacy could compound them for.

The one rejection was emideltide, the compound this site lists as DSIP. The margin was a single vote and outlets reported it both as 6 to 7 and as 7 to 6 against, a detail that gets settled when the FDA publishes the meeting minutes. Either way it fell short.

BPC-157 has the longest regulatory history: placed in Category 2 in 2023, removed in April 2026, and now recommended for 503A. BPC-157 FDA status in 2026 walks through each step. TB-500, the thymosin beta-4 fragment usually paired with it, got the same 8 to 6 result on a similar base of animal healing data and thin human work. KPV, the three amino acid anti inflammatory fragment, rounds out the healing group and was the least expected of the three to pass.

MOTS-c is the mitochondrial peptide sold for metabolic and exercise claims, and its 7 to 5 vote with two abstentions was the narrowest of the six. Semax and Epitalon are both Russian developed compounds with approvals or long use histories there and almost no Western trial data, which is likely why the committee tied them to specific indications rather than endorsing them generally.

If the FDA follows the committee on any of these, the result would be a prescription for a named patient filled by a 503A pharmacy, with pharmacist oversight, sterility testing and a labeled concentration. It would not be over the counter sale, 503B batch production or drug approval, and all six would remain prohibited by WADA under the non approved substances section.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced an intent to move roughly 14 of the 19 peptides on the FDA's Category 2 list back toward Category 1. That announcement is often conflated with the July vote and it concerns a different mechanism. Category 2 is the FDA's list of nominated substances flagged as presenting significant safety risks, which pharmacies are not supposed to compound. Category 1 is the list of nominated substances that may be compounded under enforcement discretion while the agency finishes evaluating them.

Reports said Melanotan II, GHRP-2, GHRP-6, LL-37 and PEG-MGF were expected to stay restricted. Sources conflicted on CJC-1295, with some listing it as returning and some as staying restricted, and ipamorelin was generally reported as returning. The announcement was a statement of intent, not a rule. In April 2026 the FDA removed BPC-157 and eleven other peptides from Category 2, the concrete action that followed, and removal from Category 2 is not placement in Category 1, so that step alone did not restore compounding.

The two tracks could converge. A peptide that leaves Category 2, is placed in Category 1, and is then added to the 503A list by rule would be compoundable at each of the last two stages, on different legal footing. As of October 2026 none of the six July peptides has reached either stage.

Section 503A of the Food, Drug and Cosmetic Act lets a licensed pharmacist compound a drug for an individual patient on a prescription. The bulk substance must be the active ingredient of an approved drug, the subject of a USP or NF monograph, or on a list the FDA maintains by regulation. None of the peptides on this site meets the first two tests, so the 503A bulks list is the only door, and it is built through notice and comment rulemaking.

While the FDA works through hundreds of nominations, it sorts them into interim categories. Category 1 covers substances under evaluation that may be compounded in the meantime under enforcement discretion. Category 2 covers substances the agency has flagged for significant safety concerns, which it has said should not be compounded while review continues. A substance removed from Category 2 but not placed in Category 1 sits in neither, which is where the twelve peptides removed in April 2026 landed and why that removal was misread as a green light.

The 503B list is separate. Outsourcing facilities that make larger batches without named patients need a demonstrated clinical need, and the FDA's 2026 proposal to remove semaglutide, tirzepatide and liraglutide from that list shows how narrowly it reads that. The July votes concerned 503A only. The buying guide maps compounds to the routes that are open.

The formal path after a favorable committee vote is a proposed rule in the Federal Register, a public comment period, and a final rule. Past additions to the 503A list have generally taken many months and often more than a year from vote to final rule. The FDA is also handling the GLP-1 compounding proposal, whose comment period closed June 29, 2026 with no final decision reported, and a Category 2 revision following the February announcement. All of it competes for the same staff.

Two things make this batch harder to predict than usual. The committee overrode the agency's own scientists on six substances in a row, and the FDA is not bound by the committee. It could propose all six, some, or none, with or without the indication limits attached to Semax and Epitalon. The political context is also unusual, with an HHS Secretary publicly committed to loosening peptide restrictions and agency staff on record against it. Anyone quoting a date for compounded BPC-157 is guessing.

Real news would be a proposed rule naming any of the six, a Category 1 placement for any of the twelve removed in April, or a final decision on the GLP-1 proposal. This page will be updated when one of those happens.

Nothing has changed. As of October 2026 none of the six recommended peptides is on the 503A list, none is in Category 1, and no US pharmacy can legally compound any of them. A clinic selling compounded BPC-157 or TB-500 on the strength of the July vote is ahead of the law, and its product came from the same research market as everyone else's. The are peptides safe article covers what that market does and does not guarantee.

The research route therefore carries the same burdens it did in 2024: a third party certificate with identity and purity, ideally quantity, a lot number that matches the vial, and a vendor with a track record. How to read a COA and the vendor reviews cover both. Reported dosage patterns for the six are unchanged and live on their compound pages, as ranges that appear in research and community protocols rather than recommendations.

What the vote does change is the direction of travel. For the first time an expert committee has put on record that six of the most used research peptides could be legitimately compounded on prescription, over the objection of the agency's reviewers. If any of that becomes a rule, buyers would get a product with a known concentration and sterility testing behind it. Until then the list is a recommendation, and the vial is still a reagent.